Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MIRM

MIRM - Mirum Pharmaceuticals Inc Stock Price, Fair Value and News

$100.81+1.54 (+1.55%)
Market Closed

53/100

MIRM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

53/100

MIRM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$93.63

Target 3M

$94.1

Target 6M

$94.01

MIRM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MIRM Price Action

Last 7 days

8.1%

Last 30 days

25.7%

Last 90 days

39.6%

Trailing 12 Months

107.7%

MIRM RSI Chart

MIRM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MIRM Valuation

Market Cap

5.2B

Price/Earnings (Trailing)

-125.08

Price/Sales (Trailing)

10.98

EV/EBITDA

-852.17

Price/Free Cashflow

116.9

MIRM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$93.63

Target 3M

$94.1

Target 6M

$94.01

MIRM Fundamentals

MIRM Revenue

Revenue (TTM)

471.8M

Rev. Growth (Yr)

47.17%

Rev. Growth (Qtr)

4.09%

MIRM Earnings

Earnings (TTM)

-41.4M

Earnings Growth (Yr)

120.41%

Earnings Growth (Qtr)

149.56%

MIRM Profitability

Operating Margin

79.92%

EBT Margin

-8.65%

Return on Equity

-14.18%

Return on Assets

-5.28%

Free Cashflow Yield

0.86%

MIRM Investor Care

Shares Dilution (1Y)

7.06%

Diluted EPS (TTM)

-0.86

MIRM Alerts

  • 1 major insider buys and 6 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025379.3M429.2M471.8M0
2024224.0M264.4M307.0M336.9M
202395.8M115.8M144.7M186.4M
202233.6M48.1M62.6M77.1M
202100019.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Mirum Pharmaceuticals Inc

MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
 CEO
 WEBSITEmirumpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES213

Mirum Pharmaceuticals Inc Frequently Asked Questions

MIRM is the stock ticker symbol of Mirum Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Mirum Pharmaceuticals Inc is 5.18 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MIRM's fair value in chart for subscribers.

The fair value guage provides a quick view whether MIRM is over valued or under valued. Whether Mirum Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Mirum Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MIRM.

As of Wed Jan 28 2026, MIRM's PE ratio (Price to Earnings) is -125.08 and Price to Sales (PS) ratio is 10.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MIRM PE ratio will change depending on the future growth rate expectations of investors.